RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia

Nature Medicine
Haibin XiaBeverly L Davidson

Abstract

The dominant polyglutamine expansion diseases, which include spinocerebellar ataxia type 1 (SCA1) and Huntington disease, are progressive, untreatable, neurodegenerative disorders. In inducible mouse models of SCA1 and Huntington disease, repression of mutant allele expression improves disease phenotypes. Thus, therapies designed to inhibit expression of the mutant gene would be beneficial. Here we evaluate the ability of RNA interference (RNAi) to inhibit polyglutamine-induced neurodegeneration caused by mutant ataxin-1 in a mouse model of SCA1. Upon intracerebellar injection, recombinant adeno-associated virus (AAV) vectors expressing short hairpin RNAs profoundly improved motor coordination, restored cerebellar morphology and resolved characteristic ataxin-1 inclusions in Purkinje cells of SCA1 mice. Our data demonstrate in vivo the potential use of RNAi as therapy for dominant neurodegenerative disease.

References

Dec 15, 1988·The Journal of Comparative Neurology·R W Williams, P Rakic
Jan 1, 1995·Clinical Neuroscience·H Y Zoghbi
Feb 1, 1995·Seminars in Cell Biology·H Y Zoghbi, H T Orr
Jan 26, 2002·Human Molecular Genetics·Natasha J CaplenRichard A Morgan
Jun 27, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yaohui ChaiHenry L Paulson
Sep 24, 2002·Nature Biotechnology·Haibin XiaBeverly L Davidson
Oct 3, 2002·Nature Cell Biology·David L StenoienMichael A Mancini
Nov 13, 2002·Human Gene Therapy·Masashi UrabeRobert M Kotin
Jun 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Victor M MillerHenry L Paulson
Feb 6, 2004·Nature Biotechnology·Angela ReynoldsAnastasia Khvorova
Feb 26, 2004·Lancet Neurology·Beverly L Davidson, Henry L Paulson

❮ Previous
Next ❯

Citations

Mar 11, 2005·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·G Scott RalphMimoun Azzouz
Jul 20, 2005·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Sailen Barik
Jun 3, 2006·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Masahiro WazaGen Sobue
Jul 14, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Christopher R Sibley, Matthew J A Wood
Aug 8, 2007·Applied Microbiology and Biotechnology·Alejandro NegreteRobert M Kotin
Dec 6, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Andreas H JacobsPedro Lowenstein
Jul 3, 2009·Molecules and Cells·Seongman Kang, Sunghoi Hong
Jan 3, 2006·Cellular and Molecular Neurobiology·Victor M MillerPedro Gonzalez-Alegre
Oct 13, 2007·Pharmaceutical Research·Jamie M BergenSuzie H Pun
Mar 8, 2005·Current Hypertension Reports·Koji Sakai, Curt D Sigmund
Jul 2, 2008·Current Neurology and Neuroscience Reports·Tanja Schmitz-Hübsch, Thomas Klockgether
Apr 25, 2012·Current Neurology and Neuroscience Reports·Anna Sailer, Henry Houlden
Sep 16, 2010·Current Treatment Options in Neurology·Gonzalo J Revuelta, George R Wilmot
Sep 5, 2012·Molecular Neurobiology·Pawel M SwitonskiMaciej Figiel
Apr 18, 2008·The Cerebellum·Benjamin R Underwood, David C Rubinsztein
Nov 6, 2009·The Cerebellum·Antoni Matilla-DueñasPilar Latorre
Apr 17, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Pavitra S RamachandranBeverly L Davidson
May 24, 2005·Pharmacology & Therapeutics·Ray K M Leung, Paul A Whittaker
Jul 16, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Edgardo Rodriguez-LebronRonald J Mandel
Nov 2, 2011·The Breast : Official Journal of the European Society of Mastology·Marilena V IorioElda Tagliabue
Feb 19, 2005·Drug Discovery Today·Frank Sams-Dodd
Feb 2, 2012·Expert Reviews in Molecular Medicine·Lauren M Watson, Matthew J A Wood
Jun 2, 2012·Cell Death and Differentiation·P IsaksonA Simonsen
Jul 24, 2013·Cell Research·Maria do Carmo Costa, Henry L Paulson
Jul 31, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Guy L OdomJeffrey S Chamberlain
Nov 13, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ryan L BoudreauBeverly L Davidson
Jan 29, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Naomi ChaddertonG Jane Farrar
Apr 5, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nicholas R FranichDeborah Young
Jul 9, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ayse UlusoyDeniz Kirik
Aug 11, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sergia BortolanzaDavide Gabellini
Jul 4, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Edgardo Rodríguez-LebrónHenry L Paulson
Jan 25, 2013·Molecular Therapy. Nucleic Acids·Dirk Haussecker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.